A new imaging method to predict how well cancer treatments work

A Novel Fluorescence Imaging Platform to Predict Response to Combinatorial Tyrosine Kinase Inhibitors

NIH-funded research Oregon Health & Science University · NIH-10914024

This study is testing a new imaging method to help doctors see how well cancer patients might respond to a combination of targeted therapies, so they can create more personalized treatment plans based on the unique features of each patient's tumor.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionOregon Health & Science University NIH-funded
Lab location1 site (Portland, United States)
Project IDNIH-10914024 on NIH RePORTER

What this research studies

This research focuses on developing a novel fluorescence imaging platform that can help predict how well patients with cancer will respond to combinatorial tyrosine kinase inhibitors (TKIs). By using advanced imaging techniques, the study aims to visualize and quantify the interaction between these drugs and their targets within tumors. This approach addresses the challenges of tumor heterogeneity and drug resistance, which often complicate treatment outcomes. Patients may benefit from more personalized treatment plans based on their tumor's specific characteristics.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers that are known to be treated with tyrosine kinase inhibitors.

Not a fit: Patients whose cancers do not involve tyrosine kinase pathways may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective and tailored cancer treatments for patients.

How similar studies have performed: Other research has shown promising results using similar imaging techniques to improve cancer treatment outcomes.

Where this research is happening

Portland, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancer ModelCancer PatientCancer TreatmentCancerModelCancers
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.